The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Leveraging high variant allele frequencies (VAF) of DNA damage repair (DDR) mutations (muts) in liquid biopsy (LBx) as a surrogate for germline testing: Implications for precision medicine.
 
Sagal Pannu
No Relationships to Disclose
 
Arifa Bibi
No Relationships to Disclose
 
Trey Gradnigo
No Relationships to Disclose
 
Niveditha Popuri
No Relationships to Disclose
 
Jada Roberts
No Relationships to Disclose
 
Adanma Ayanambakkam
Consulting or Advisory Role - AVEO; Pfizer/Astellas
 
Susanna Ulahannan
Consulting or Advisory Role - AstraZeneca; Eisai; IgM Biosciences
Research Funding - Abbvie (Inst); Adlai Nortye (Inst); ArQule (Inst); Artios (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); atreca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CicloMed (Inst); Eisai (Inst); Erasca, Inc (Inst); evelo biosciences (Inst); Exelixis (Inst); Exelixis (Inst); Exthera medical (Inst); G1 Therapeutics (Inst); GlaxoSmithKline (Inst); IgM Biosciences (Inst); immunitas (Inst); Incyte (Inst); Jazz Pharmaceuticals (Inst); Jazz Pharmaceuticals (Inst); Klus Pharma (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); NGM Biopharmaceuticals (Inst); Omega Therapeutics (Inst); OncoMed (Inst); Pfizer (Inst); Pionyr (Inst); Purple Biotech (Inst); Qurgen (Inst); Regeneron (Inst); Revolution Medicines (Inst); Sapience Therapeutics (Inst); Synermore biologics (Inst); Takeda (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tempest Therapeutics (Inst); Tesaro (Inst); Theradex (Inst); Totus Medicines (Inst); Tvardi Therapeutics (Inst); Tvardi Therapeutics (Inst); Vigeo Therapeutics (Inst)
 
Raid Aljumaily
Research Funding - Abbvie (Inst); Alliance Foundation Trials (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Baxalta (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Checkpoint Therapeutics (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Huntsman Cancer Institute (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Syneos Health (Inst); Tesaro (Inst)
 
Minh Phan
No Relationships to Disclose
 
Ayesha Aijaz
No Relationships to Disclose
 
Hassan Abushukair
No Relationships to Disclose
 
Christina Caldwell
No Relationships to Disclose
 
Max Bouvette
No Relationships to Disclose
 
Nirmal Choradia
No Relationships to Disclose
 
Kathleen Moore
Leadership - GOG Partners; NRG Oncology (Inst)
Honoraria - Astellas Medivation; Clinical Education Alliance; Haymarket Medical Education; IDEOlogy Health; Medscape; The Clearity Foundation
Consulting or Advisory Role - AADi; Abbvie; ADC Therapeutics; AstraZeneca; BioNTech SE; Blueprint Medicines (Inst); Bristol Myers Squibb Foundation; Caris Life Sciences; Clovis Oncology; Corcept Therapeutics; Daiichi Sankyo Europe GmbH; Duality Biologics (Inst); Eisai; Elucida Oncology; Exelixis; Genentech/Roche; GlaxoSmithKline/Tesaro (Inst); immunocore; Immunogen; Iovance Biotherapeutics; Janssen Oncology; Loxo/Lilly; Merck; Mersana (Inst); Novocure; ProfoundBio; Regeneron; Roche; Sanofi/Aventis; Schrodinger (Inst); seagen; T knife; Takeda Science Foundation; Tango Therapeutics; Third Arc; Tubulis GmbH; Verastem/Pharmacyclics; Xencor; zentalis; zymeworks
Research Funding - Amgen (Inst); artios (Inst); AstraZeneca (Inst); Daiichi Sankyo/Lilly (Inst); Immunocore (Inst); Immunogen (Inst); Merck (Inst); Regeneron (Inst); Verastem (Inst)
Other Relationship - GOG Partners (Inst)
 
Debra Richardson
Honoraria - Zentalis
Consulting or Advisory Role - Abbvie; AstraZeneca; Daiichi Sankyo/UCB Japan; Eisai; Genmab; GlaxoSmithKline; Immunogen; Incyclix Bio; Mersana; ProfoundBio; Repare Therapeutics
Research Funding - A2A Pharmaceuticals (Inst); aadi (Inst); Acrivon Therapeutics (Inst); Allorian (Inst); Aravive (Inst); Arch Oncology (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); CanariaBio (Inst); Celsion (Inst); Clovis Oncology (Inst); DualityBio (Inst); GlaxoSmithKline (Inst); Hookipa Biotech (Inst); Immunogen/Abbvie (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); Nimbus Therapeutics (Inst); Nurix (Inst); OnCusp Therapeutics (Inst); Plexxikon (Inst); PMV Pharma (Inst); ProfoundBio (Inst); Scorpion Therapeutics (Inst); Shattuck Labs (Inst); Tubulis GmbH (Inst); Valerion Therapeutics, LLC (Inst)
Travel, Accommodations, Expenses - Genmab; Society of Gynecologic Oncology
 
Naoko Takebe
No Relationships to Disclose
 
Abdul Rafeh Naqash
Honoraria - NGM Biopharmaceuticals
Consulting or Advisory Role - Astellas Pharma; foundation me
Travel, Accommodations, Expenses - American Society for Radiation Oncology; ASCO; Binacea; Foundation Medicine; Jazz Pharmaceuticals (Inst); Society for Immunotherapy of Cancer